JPWO2020047322A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020047322A5 JPWO2020047322A5 JP2021511584A JP2021511584A JPWO2020047322A5 JP WO2020047322 A5 JPWO2020047322 A5 JP WO2020047322A5 JP 2021511584 A JP2021511584 A JP 2021511584A JP 2021511584 A JP2021511584 A JP 2021511584A JP WO2020047322 A5 JPWO2020047322 A5 JP WO2020047322A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- domain
- binding
- pharmaceutical composition
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 74
- 102000037865 fusion proteins Human genes 0.000 claims description 57
- 108020001507 fusion proteins Proteins 0.000 claims description 57
- 206010028980 Neoplasm Diseases 0.000 claims description 47
- 239000003446 ligand Substances 0.000 claims description 43
- 201000011510 cancer Diseases 0.000 claims description 35
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 30
- 108010029697 CD40 Ligand Proteins 0.000 claims description 24
- 102100032937 CD40 ligand Human genes 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 22
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 20
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 20
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 20
- 102000004473 OX40 Ligand Human genes 0.000 claims description 18
- 108010042215 OX40 Ligand Proteins 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 13
- 101710165474 Tumor necrosis factor receptor superfamily member 5 Proteins 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 10
- 230000003993 interaction Effects 0.000 claims description 10
- 229960003301 nivolumab Drugs 0.000 claims description 10
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 9
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 9
- 239000000556 agonist Substances 0.000 claims description 9
- 230000004083 survival effect Effects 0.000 claims description 9
- 108010050904 Interferons Proteins 0.000 claims description 8
- 229940044665 STING agonist Drugs 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 229960002621 pembrolizumab Drugs 0.000 claims description 6
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 230000004580 weight loss Effects 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims description 3
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 3
- 206010027145 Melanocytic naevus Diseases 0.000 claims description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 208000007256 Nevus Diseases 0.000 claims description 3
- 206010030113 Oedema Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 3
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 206010047741 Vulval cancer Diseases 0.000 claims description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 201000009036 biliary tract cancer Diseases 0.000 claims description 3
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 3
- 201000000220 brain stem cancer Diseases 0.000 claims description 3
- 201000007455 central nervous system cancer Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000010918 connective tissue cancer Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 208000024519 eye neoplasm Diseases 0.000 claims description 3
- 230000003325 follicular Effects 0.000 claims description 3
- 201000003444 follicular lymphoma Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 3
- 230000000527 lymphocytic effect Effects 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000025113 myeloid leukemia Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000008106 ocular cancer Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 201000002628 peritoneum cancer Diseases 0.000 claims description 3
- 210000003800 pharynx Anatomy 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 230000002485 urinary effect Effects 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- 229940126253 ADU-S100 Drugs 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 229950007217 tremelimumab Drugs 0.000 claims description 2
- 229940125117 ulevostinag Drugs 0.000 claims description 2
- XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 claims description 2
- 229940055760 yervoy Drugs 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 10
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 10
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 description 52
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 29
- 102000007346 Hepatitis A Virus Cellular Receptor 2 Human genes 0.000 description 29
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100031351 Galectin-9 Human genes 0.000 description 1
- 101710121810 Galectin-9 Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 210000005008 immunosuppressive cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862724597P | 2018-08-29 | 2018-08-29 | |
| US201862724600P | 2018-08-29 | 2018-08-29 | |
| US62/724,597 | 2018-08-29 | ||
| US62/724,600 | 2018-08-29 | ||
| US201862734951P | 2018-09-21 | 2018-09-21 | |
| US201862734950P | 2018-09-21 | 2018-09-21 | |
| US62/734,950 | 2018-09-21 | ||
| US62/734,951 | 2018-09-21 | ||
| US201962793235P | 2019-01-16 | 2019-01-16 | |
| US62/793,235 | 2019-01-16 | ||
| US201962832830P | 2019-04-11 | 2019-04-11 | |
| US62/832,830 | 2019-04-11 | ||
| US201962890217P | 2019-08-22 | 2019-08-22 | |
| US62/890,217 | 2019-08-22 | ||
| PCT/US2019/048916 WO2020047322A1 (en) | 2018-08-29 | 2019-08-29 | Combination therapies comprising tim-3-based chimeric proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022503621A JP2022503621A (ja) | 2022-01-12 |
| JP2022503621A5 JP2022503621A5 (https=) | 2022-09-06 |
| JPWO2020047322A5 true JPWO2020047322A5 (https=) | 2022-09-06 |
Family
ID=69643783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021511584A Pending JP2022503621A (ja) | 2018-08-29 | 2019-08-29 | Ｔｉｍ－３系キメラタンパク質を含む併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210179689A1 (https=) |
| EP (1) | EP3844185A4 (https=) |
| JP (1) | JP2022503621A (https=) |
| CN (1) | CN112888706A (https=) |
| AU (1) | AU2019328305A1 (https=) |
| CA (1) | CA3109349A1 (https=) |
| IL (1) | IL281123A (https=) |
| MX (1) | MX2021002291A (https=) |
| WO (1) | WO2020047322A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017006320A (es) * | 2014-11-17 | 2017-08-10 | Genentech Inc | Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1. |
| BR112017016681A2 (pt) * | 2015-02-06 | 2018-04-10 | Heat Biologics Inc | vetor de coexpressão de vacina e moléculas coestimulatórias |
| RU2766200C1 (ru) * | 2015-10-01 | 2022-02-09 | Хит Байолоджикс, Инк. | Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков |
| US20170145103A1 (en) * | 2015-11-23 | 2017-05-25 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
| MX2019009812A (es) * | 2017-02-27 | 2019-10-14 | Shattuck Labs Inc | Proteinas quimericas basadas en tigit y light. |
-
2019
- 2019-08-29 AU AU2019328305A patent/AU2019328305A1/en not_active Abandoned
- 2019-08-29 MX MX2021002291A patent/MX2021002291A/es unknown
- 2019-08-29 WO PCT/US2019/048916 patent/WO2020047322A1/en not_active Ceased
- 2019-08-29 EP EP19856345.4A patent/EP3844185A4/en not_active Withdrawn
- 2019-08-29 JP JP2021511584A patent/JP2022503621A/ja active Pending
- 2019-08-29 US US17/265,684 patent/US20210179689A1/en not_active Abandoned
- 2019-08-29 CA CA3109349A patent/CA3109349A1/en active Pending
- 2019-08-29 CN CN201980070366.7A patent/CN112888706A/zh active Pending
-
2021
- 2021-02-25 IL IL281123A patent/IL281123A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ferris et al. | Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation | |
| CA2953276C (en) | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders | |
| JP2023112132A (ja) | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 | |
| JP2020508068A5 (https=) | ||
| EP4537904A2 (en) | Multi-specific binding proteins and improvements thereon | |
| IL279146B1 (en) | Reverse chimeric universal antigen receptor (RevCAR) expressing immune cells targeting multiple and different antigens, method of making them and use thereof for treating cancer, infections and autoimmune disorders | |
| JP2020508329A5 (https=) | ||
| US12545727B2 (en) | Antibodies specific to human Nectin-2 | |
| JP2022512541A5 (https=) | ||
| JP2022511286A5 (https=) | ||
| JP2020508063A5 (https=) | ||
| JP2022527643A (ja) | がん治療のための免疫療法 | |
| JP2022513421A5 (https=) | ||
| TW202108629A (zh) | 用於t細胞活化之抗體 | |
| CN114599398A (zh) | 用gm-csf拮抗剂治疗癌症 | |
| CA3075717A1 (en) | Combination treatment for cancer | |
| CN114616251B (zh) | 靶向PD-1和TGFβ的重组蛋白 | |
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| JP2022512539A5 (https=) | ||
| JPWO2020047328A5 (https=) | ||
| CN111867598A (zh) | 肿瘤免疫赋活剂 | |
| JPWO2020047319A5 (https=) | ||
| JPWO2020047322A5 (https=) | ||
| JP2022503621A5 (https=) | ||
| CN118221826A (zh) | 一种结合人cd33和cd3的双特异性抗体 |